The enzyme Nicotinamide N-methyltransferase (NNMT) catalyzes the methylation of nicotinamide and other pyridines, playing a pivotal role in the biotransformation and detoxification of many drugs and xenobiotic compounds. Several tumours have been associated with abnormal NNMT expression, however its role in tumour development remains largely unknown. In this study we investigated expression levels of Nicotinamide N-methyltransferase in a cancer cell line and we evaluated the effect of shRNA-mediated silencing of NNMT on cell proliferation. Cancer cells were examined for NNMT expression by semiquantitative RT-PCR and Western blot analysis. A HPLC-based catalytic assay was performed to assess enzyme activity. Cells were transfected with four shRNA plasmids against NNMT and control cells were treated with transfection reagent only (mock). The efficiency of gene silencing was detected by Real-Time PCR and Western blot analysis. MTT cell proliferation assay and the soft agar colony formation assay were then applied to investigate the functional changes in cancerous cell. NNMT mRNA was detected in cancer cells, showing a very high expression level. In keeping with the results of RT-PCR analysis, the protein level and NNMT enzyme activity were particularly high in KB cells. ShRNA vectors targeted against NNMT efficiently suppressed gene expression, showing inhibition observed at both the mRNA and protein levels. Down-regulation of NNMT significantly inhibited cell proliferation and decreased colony formation ability on soft agar. The present data support the hypothesis that the enzyme plays a role in tumour expansion and its inhibition could represent a possible molecular approach to the treatment of cancer.
tumours usually is based on surgery or radiation, with or without concomitant chemotherapy. Nevertheless, despite continuous improvements in cancer management, most deaths from cancer result from the progressive growth and late detection of metastases that are usually resistant to conventional therapies. Delayed detection is likely to be a primary reason for the poor survival rate of cancer patients, and this supports the imperative need for the identification of sensitive biomarkers to improve early detection of cancer and to provide more information on the tumour biology. The identification of reliable and clinically applicable markers through gene expression profiling is essential to predict the aggressiveness of malignancies and disease outcome (2) , as well as to highlight new potential molecular targets for cancer chemotherapy.
Nicotinamide N-Methyltransferase (NNMT), an enzyme involved in the biotransformation of many xenobiotics, represents a potential cancer biomarker that was found overexpressed in several malignancies such as glioblastoma, stomach adenocarcinoma, papillary thyroid cancers, bladder, colorectal, pancreatic and lung cancer. In our previous reports we evaluated NNMT expression in renal (RCC) and oral squamous cell carcinoma (OSCC). In renal cell carcinoma NNMT mRNA was overexpressed in 100% of clear cell renal cell carcinomas (ccRCCs) compared to adjacent noncancerous tissue. Moreover, NNMT expression level in ccRCC showed an inverse correlation with tumor size, suggesting a role of the enzyme in tumour growth (3) . In oral squamous cell carcinoma NNMT upregulation inversely correlated with pT, pathological staging and lymph node metastasis (4) . Furthermore, Kaplan-Meier analysis showed an improved overall survival rate for patients bearing tumours with higher NNMT expression levels than patients with tumours with lower NNMT expression, although without reaching statistical significance (5) . These results seem to suggest that NNMT may have potential as a prognostic marker and a therapeutic target for cancer. To explore the role played by NNMT in cancer cell metabolism, in this report we examined enzyme expression in a human cancer cell line and the effect of NNMT RNA interference-mediated downregulation on cell proliferation.
MATERIALS AND METHODS

Cel/line and reagents
KB cancer cell line (human epithelial.carcinoma cell line), obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA), was selected for this study on the basis of its ability to express very high levels of NNMT. Cells were cultured in DMEM-FI2 supplemented with 10% fetal bovine serum, 100 Ulml of penicillin and 100 ug/ml of streptomycin at 37°C in a humidified 5% CO 2 incubator.
RNA Extraction
Cells from culture were pelleted and total RNA was extracted using SV Total RNA Isolation System (Promega, Madison, WI, USA), according to the manufacturer's protocol. The quantity and quality of RNA were assessed spectrophotometrically at 260 nm and 280 nm, and confirmed by electrophoresis on denaturated 1% agarose gel.
Semiquantitative RT-PCR
Total RNA (2 ug) was reverse transcribed in a total volume of 25 III for 60 minutes at 42°C with M-MLV Reverse Transcriptase (Promega, Madison, WI, USA) using oligotdeoxythymidinej., primers. To control the efficiency of cDNA synthesis, I III cDNA was amplified for the~-actin gene. cDNA mixture (1 Ill) was subjected to RT-PCR in a total of 25 III with GoTaq Flexi DNA Polymerase (Promega, Madison, WI, USA). Gene specific primers for human NNMT and~-actin were designed based on DNA sequences in the National Center for Biotechnology. Primer sequences are summarized in Table I . Optimal PCR amplification conditions were determined and PCR products were electrophoresed on 2% agarose gel, stained with ethidium bromide, and photographed.
Real-Time quantitative PCR
Differential gene expression measurements (silenced vs mock cells) was achieved by quantitative Real Time-PCR analysis, performed using the MyiQ Single Color Real-Time PCR Detection System (Bio-Rad Laboratories, Hercules, CA). cDNA, generated as described above, was used as template. To avoid false-positive results attributable to amplifying contaminating genomic DNA in the cDNA preparation, all primers were selected to flank an intron. Also, PCR efficiency was tested for both primer pairs and found to be close to I. Primer sequences for NNMT and~-actin are summarized in Table I . The 2 genes were run in duplicate for 40 cycles at 94°C for 30 seconds and 56°C for 30 seconds using SYBR® Green chemistry. All samples were tested in triplicate with the reference gene p-actin for data normalization to correct for variations in RNA quality and quantity. Direct detection of PCR products was monitored by measuring the fluorescence produced by SYBR® Green I dye binding to double strand DNA after every cycle. These measurements were then plotted against cycle numbers. The parameter threshold cycle (C,) was defined as the cycle number at which the first detectable increase above the threshold in fluorescence was observed. Fold changes in relative gene expression were calculated by 2-6 <6 CI) where~C, = C, (NNMT) -C, (B-actin) and~(~C,) =~C, (silenced cells) -~CI (mock cells).
Western blot analysis
To evaluate NNMT protein expression level, cellular samples were analyzed by Western blot. Cell extracts were prepared with lysis buffer (phosphate buffered saline containing 1% Nonidet P40, 0.1% sodium dodecyl sulfate, I mM phenylmethylsulfonyl fluoride and 2 ug/ml aprotinin). Protein concentration was measured by the Bradford method using bovine serum albumin as the standard (6) . Samples containing 50 ug protein were subjected to 15% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to polyvinylidene fluoride membranes. After regular blocking and washing the membranes were incubated with chicken polyclonal antibody (Sigma-Aldrich, St. Luis, MO) (I: 1,000 dilution) against NNMT for 1 hour, followed by incubation with horseradish peroxidase conjugated rabbit anti-chicken IgG (Sigma-Aldrich, St. Luis, MO) (I :50,000 dilution) for 1 hour. NNMT protein was visualized using enhanced SuperSignal West Femto Maximum Sensitivity chemiluminescent substrate (Pierce, Rockford, IL, USA).
NNMT enzyme assay
An HPLC-based catalytic assay was performed to analyze NNMT activity. A frozen cell pellet (5x 10 6 cells) was suspended in 200~I of cold lysis buffer (50 mM tris-HCI, pH 8.6, 2 ug/ml aprotinin, 1 mM phenylmethylsulfonyl fluoride, 1 mM dithiothreitol, 1% Nonidet P40) and Y2 vol glass beads. The suspension was vortexed at maximum speed for 2 minutes and then chilled on ice for 2 minutes. The homogenate was centrifuged at 16,000 x g for 10 minutes at 4°C. The supernatant was kept at 4°C until assayed. The standard assay mixture contained 50 mM tris-HCI, pH 8.6, 1 mM dithiothreitol, 5 mM nicotinamide, 0.5 mM S-adenosyl-L-methionine and the appropriate amount of enzyme sample to a final volume of 350 ul, The reaction was started by adding the substrate S-adenosyl-L-methionine. Incubations were carried out at 37°C for 30 and 60 minutes. The reaction was stopped by adding 100~I assay mixture to 50~I icecold 1.2 M HCIO 4' After 10 minutes at O°C proteins were removed by 1 minute of centrifugation in a microfuge and 130~I perchloric acid supernatant were then neutralized by adding 35~I 0.8 M K 2COJ • The KCI0 4 so formed was removed by centrifugation. 100~I of the neutralized supernatant was injected into a high performance liquid chromatography system 10 Dvp-uv-vis photodiode array detector (Shimadzu, Duisburg, Germany) using a 250 x 4.6 mm inner diameter Supelcosil® LC-18 5 urn reversed phase column. Elution conditions were as previously described (7) . Enzyme activities were tested by measuring the amount of N'-methylnicotinamide produced, as determined by the peak areas of the separated compound with 1 U activity representing the formation of 1 nmol N'methylnicotinamide per hour of incubation at 37°C.
ShRNA plasmid vector transfection
Cancer cells were seeded (2x 10 5 cells/well) in sixwell plates. After 24 h of incubation, they reached 50-70% confluence and were transfected with four shRNA plasmids against NNMT (pLKO.I-330, 1-448, 1-711, 1-801), purchased from Sigma (Sigma-Aldrich, St. Luis, Table I . Gene specific primers usedfor RT-PCR and quantitative Real-Time PCR. respectively.
Gene
Sequence 
Cell proliferation assay
Cells were seeded in 96-well flat-bottom plates at 10 4 cells per well in DMEM-FI2 supplemented with 10% FBS and antibiotics . The cells were allowed to attach overnight and cell proliferation was evaluated for up to 4 days by a colorimetric MTT assay. Briefly, 10 J.lI of MTT reagent (5 mg/ml in PBS) was added to the cells and after incubation for 4 h at 37°C, the medium was removed and 200 J.lI of isopropanol were added . The absorbance was read at 595 nm using an ELISA plate reader. Experiments were repeated three times. expression was detected at the protein level by Western blot analysis. Western blot was performed using protein extracts prepared from KB cells and NNMT level was examined by Immunoblotting with a purified anti-NNMT-specific chicken antibody. The analysis showed a single band at approximately 30 kDa, which corresponds to the known molecular mass of NNMT, with high immunoreactivity intensity (Fig. IB) .
NNMT catalytic activity assay
A HPLC-based catalytic assay was performed to assess NNMT activity. In keeping with the results of RT-PCR and Western blot analysis, the level of NNMT activity was particularly high in the KB cells (mean specific activity 1.7 U/mg) compared to values measured in other cell lines (mean specific activity 0.4 U/mg).
Efficiency of RNA interference
In order to investigate how NNMT gene is involved in carcinogenesis, KB cells were transfected with four shRNA plasmids against NNMT (pLKO.I-330, 1-448, 1-711 , 1-801) and control cells were treated with transfection reagent only (mock), as described above. To examine the specific effects 
. NNMT expression analysis in KB cells. A) RT-PCR analysis was performed to explore NNMT mRNA expression. fJ-actin served as internal control. B) Western blot analysis was performed as described in Materials
and Methods: 50 f.1g ofprotein from 15% SDS-PAGE were transferred to polyvinilidenefluoride membrane. Blot was probed with chicken anti-NNMT antibody, and detected with enhanced chemiluminescence.
Soft agar colony formation assay
Soft agar colony-forming assays were performed in triplicate. KB cells (10 4 cells/well) were seeded in 24-well plates in DMEM medium containing 0.35% low melting point (LMP) agar overlying a 0.7% LMP agar layer. The cells were cultured at 37°C in 5% CO 2 for 30 days. Every 7 days 500 J.lI offresh medium was added to each well and visible colonies were photographed.
RESULTS ·
RT-PCR
To explore the expression of NNMT mRNA in cancer cell line, total RNA isolated from KB cells was subjected to semiquantitative RT-PCR, as described in Materials and Methods. A transcript of 238 bp, corresponding to NNMT mRNA, was detected in the cellular sample (Fig. IA) .
Western blot analysis
To confirm the above-reported results, NNMT of shRNA treatment on NNMT expression, the mRNA and protein NNMT expression levels were determined by Real-Time PCR and Western blot analysis, respectively. Compared with mock, both mRNA and protein levels of NNMT were reduced after transfection. Mean NNMT mRNA expression was 3.33-fold lower in transfected compared to mock cells ( Fig. 2A) . Consistent with the results of Real-Time PCR, lanes loaded with equal protein amounts showed that NNMT expression was markedly decreased in transfected samples compared with that detected in mock cells (Fig. 2B) .
Effect ofshRNA targeting NNMT on cell growth
To investigate the function of NNMT gene in cancer cell and analyse the biological effect associated with NNMT downregulation, cancer cells, transfected with the most efficient shRNA plasm ids against NNMT (pLKO.I-448, 1-80I), were selected for further analyses. The effect of NNMT silencing on cell proliferation was assessed by MTT assay. As shown in Fig. 3A , efficient downregulation of NNMT resulted in markedly reduced cell proliferation. A reduction of cell growth was observed only for transfected cells and it was detectable already 48 h after transfection. In contrast, mock cell proliferation was not inhibited over the whole period of observation. Cell growth inhibition was confirmed by soft agar colony-forming assay. Most of the colonies observed in NNMT silenced cells were much smaller than those in the mock, and the number of colonies formed by transfected cells was lower than the number formed by mock cells (Fig.3B) .
DISCUSSION
During the last decades, the increased understanding and molecular characterization of tumour led to considerable improvements and technical innovation in cancer diagnosis and treatment. Nevertheless, despite substantial developments in both therapeutic and diagnostic strategies, the prognosis of tumour is often unfavourable and most patients still die of their diseases, indicating that the development of novel agents is still an important priority. In fact, little is known about the molecular events that govern tumour progression (8) (9) .
We previously evaluated expression levels of Nicotinamide N-Methyltransferase (NNMT), an enzyme involved in the drug metabolism process, in renal and oral squamous cell carcinoma (0SCC). Our data revealed an upregulation ofNNMT in clear cell renal cell carcinomas (ccRCCs) and in OSCC samples compared to adjacent non-cancerous tissue, suggesting the possibility of NNMT as a diagnostic marker and a therapeutic target for these kinds of tumour (3) (4) .
In the present study, to explore the possibility of NNMT as an effective molecular target for cancer therapy, we employed an RNA interference technique to silence endogenous NNMT expression in a human cancer cell line and analysed phenotypic changes of transiently transfected KB cancer cells. NNMT was silenced by transfection of four NNMT-directed short hairpin RNA (shRNA) vectors. The expression change ofNNMTwas examined by Real Time-PCR and Western blot analysis, showing inhibition rates around 70%. Efficient down-regulation of NNMT resulted in significantly reduced cell proliferation. Cell growth inhibition was confirmed by a decreased capability of NNMT silenced KB cells to form colonies in soft agar.
The enzyme Nicotinamide N-methyltransferase (NNMT) catalyzes the transmethylation from Sadenosylmethionine to nicotinamide and to some other azaheterocycles, playing a pivotal role in the biotransformation and detoxification of many xenobiotics (10) (11) (12) (13) . N-methylation has been proposed as a metabolic pathway for nicotinamide excretion, and NNMT is the only enzyme known to use nicotinamide as methyl acceptor substrate. In this regard NNMT expression levels could affect all fundamental cellular events involving nicotinamide, modulating its excretion after N-methylation. As already mentioned, NNMT catalyzes the formation ofN'-methylnicotinamide, therefore, NNMT activity may be involved in regulating the biological activity of this endogenous compound. It has recently become apparent that N'-methylnicotinamide possesses anti-inflammatory (14) , anti-thrombotic (15) , vasoprotective (16) , and gastroprotective (17) properties, and its levels were found altered in some diseases including hepatic cirrhosis (18) and atherosclerosis (19) . Increased NNMT expression was detected in chronic obstructive pulmonary disease (COPD) (20) (21) , and in Parkinson's disease, in which enhanced enzyme activity seems to lead to the production of toxic N-methylpiridinium compounds that have been advanced as possible neurotoxins underlying nigrostriatal degeneration (22) . In addition to RCC and OSCC, NNMT dysregulation has been detected in several human cancers, such as glioblastoma (23), stomach adenocarcinoma (24) (25) , papillary thyroid cancers (26) (27) , colorectal cancer (28) , hepatocellular carcinoma (29) , bladder, lung and pancreatic cancer (30) (31) (32) . Although several tumours have been associated with abnormal NNMT expression, the biological significance of alterations in NNMT activity in various pathological conditions remains largely unknown. The results obtained in our previous studies seem to suggest that NNMT may be involved in the early phases of carcinogenesis and may participate in tumour growth, however, the function of NNMT in cancer cell metabolism is still unclear. Review of the literature reveals only a few reports concerning NNMT function in cancer cell lines. Depletion of NNMT in human bladder cancer cells was found to be associated with decreased cell proliferation, making this protein an interesting target for therapy (30) . Moreover, a recent study on COPD (chronic obstructive pulmonary disease) revealed that upregulation of NNMT in cultured skeletal myoblasts improved proliferation and migration of these cells and protected them against oxidant-derived injury and death (21) .
In our current study, NNMT mRNA and protein levels were detected in KB cell line, and we used vector-based siRNA against NNMT to analyse the functional importance of NNMT expression in the cell metabolism. We found markedly significant differences of NNMT expression before and after silencing the NNMT gene. NNMT downregulation resulted in significant decrease of cell proliferation and colony formation ability on soft agar. Although further studies are necessary to characterize the function of NNMT in cancer cell and to clarify its role in cell metabolism, the present study seems to suggest that NNMT has an impact on cancer cell proliferation, as supported by previous reports. In fact, in comparison to mock cells, the treatment with shRNA vectors targeted against NNMT, efficiently suppressed gene expression and exhibited a clear inhibitory effect on cell growth. Therefore, NNMT could represent a key molecule associated with cell proliferation. Our results suggest a potential role of NNMT in preserving cell viability and its inhibition could represent a possible molecular approach to the treatment of cancer.
